CollPlant received CE Mark approval for Vergenix™STR soft tissue repair matrix for the treatment of tendinopathy. EU launch is anticipated in coming months.
Initial study results released in 2015 indicated that, of ten patients in a 20-patient clinical trial of VergenixSTR, 80% of subjects reported improvement in pain and arm functionality with an increase in arm strength. Final trial results were announced in 1Q16.
CollPlant received CE Mark approval for Vergenix™STR soft tissue repair matrix for the treatment of tendinopathy. EU launch is anticipated in coming months.
Initial study results released in 2015 indicated that, of ten patients in a 20-patient clinical trial of VergenixSTR, 80% of subjects reported improvement in pain...
CollPlant received CE Mark approval for Vergenix™STR soft tissue repair matrix for the treatment of tendinopathy. EU launch is anticipated in coming months.
Initial study results released in 2015 indicated that, of ten patients in a 20-patient clinical trial of VergenixSTR, 80% of subjects reported improvement in pain and arm functionality with an increase in arm strength. Final trial results were announced in 1Q16.
Copy to clipboard 
